Dr. Reddy's Laboratories Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 36.6x vs industry 50.2x)
- Low debt relative to equity (D/E 0.2x)
Concerns
Today's Price Action
The stock closed at ₹1,335.4, unchanged from the previous session. Trading activity matched the 20‑day average volume of 28,39,036 shares, indicating a neutral market stance with neither significant buying nor selling pressure today.
Valuation Snapshot
The trailing P/E stands at 36.6, markedly higher than the implicit sector benchmark of zero, suggesting a premium valuation relative to peers. A return on equity of 11.2 % points to modest profitability, though it remains below the threshold generally regarded as high‑quality.
Key Levels to Watch
The current price sits roughly halfway between the 52‑week low of ₹1,080 and the high of ₹1,415, providing a balanced perspective on upside and downside potential. Open‑interest clusters in the nearby ₹1,300‑₹1,350 band have historically acted as soft support/resistance zones, and a breakout above ₹1,415 would test the recent swing high, while a slip below ₹1,080 could trigger further downside scrutiny.
Data Summary
Key metrics include a market‑cap listed as “₹0 Cr,” a P/B ratio of zero, and a P/E of 36.6, with volume precisely matching the 20‑day average. The stock trades within its annual range, and its ROE of 11.2 % reflects steady, albeit unspectacular, earnings generation.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
DRREDDY · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 26.65% | 26.65% | 26.65% | 26.64% | 26.64% | 26.64% |
| FII | 28.62% | 29.13% | 27.68% | 27.53% | 26.85% | 25.75% |
| DII | 18.65% | 18.31% | 20.72% | 21.48% | 22.89% | 25.63% |
| Public | 25.89% | 25.73% | 24.78% | 24.20% | 23.46% | 21.69% |
| Others | 0.18% | 0.17% | 0.17% | 0.16% | 0.16% | 0.29% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
To consider the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ending on June 30, 2026
Dividend - Rs 8 Per Share
To consider and approve the financial results for the quarter and year ending March 31, 2026
To consider and approve the financial results for the period ended March 31, 2026
To recommend final dividend, if any, for the Financial year 2025-26
Dividend - Rs 8 Per Share
Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share
Annual General Meeting/Dividend - Rs 40 Per Share
Annual General Meeting/Dividend - Rs 40 Per Share
Latest News
All newsDr. Reddy's gets DCGI nod for Zytorvi® in esophageal cancer
*Dr. Reddy's gets DCGI nod for Zytorvi® in esophageal cancer* — Dr. Reddy's Laboratories has received DCGI approval for Zytorvi® (toripalimab) for advanced esophageal squamous cell carcinoma, its second approved indication in India. This expands the drug’s market potential in oncology. The approval strengthens Dr. Reddy’s position in the immuno-oncology space. 📊 *STOCKS:* $DRREDDY | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Approval
Dr. Reddy's to announce earnings on Oct 7, 2026
*Dr. Reddy's to announce earnings on Oct 7, 2026.* The company has informed the exchange about an upcoming earnings call. This event will provide insights into its quarterly financial performance. Traders should watch for guidance and margin trends. 📊 *STOCKS:* $DRREDDY | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
US sanctions on Iran may impact Indian pharma, rice exports
*US sanctions on Iran may impact Indian pharma, rice exports.* Indian pharmaceutical and rice exporters face disruption due to tightening US sanctions on Iran. Key players like **SUNPHARMA**, **DRREDDY**, and **CIPLA** may see reduced shipments as trade channels dry up. Iranian market contributes **~$200M** to Indian pharma exports annually. 📊 *STOCKS:* SUNPHARMA, DRREDDY, CIPLA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Dr. Reddy's to host earnings call on July 13, 2026
Dr. Reddy's Laboratories has announced an upcoming earnings call scheduled for July 13, 2026. The company filed this intimation with the stock exchange as part of its regular disclosure norms. No financial figures or strategic updates were released in this notice. Traders may anticipate Q4 results and guidance during the call. 📊 *STOCKS:* DRREDDY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Dr. Reddy's shares unchanged after investor meet
Dr. Reddy's Laboratories held an analyst and institutional investor meet, with a recording shared via NSE. No new financial updates or guidance changes were announced. The event was primarily informational, following recent quarterly results. Traders saw no immediate catalyst for price movement. 📊 *STOCKS:* DRREDDY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Dr. Reddy's hosts analyst call for investor updates
*Dr. Reddy's hosts analyst call for investor updates* — Dr. Reddy's Laboratories held a conference call with analysts and institutional investors to share business updates. The company did not disclose any major financial figures or strategic shifts. 📊 *STOCKS:* DRREDDY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorCall
Dr. Reddy's discloses regulatory update under SEBI norms
*Dr. Reddy's discloses regulatory update under SEBI norms.* This filing is made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, indicating a routine compliance disclosure. No financial or operational impact is evident from the announcement. Such updates are standard for listed companies. 📊 *STOCKS:* DRREDDY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #SEBI
Dr. Reddy's shares up on newspaper publication notice
*Dr. Reddy's shares rose on news of a newspaper publication filing.* The company informed the exchange about the publication, a routine regulatory disclosure. No financial impact or major development was indicated. Such filings are typically part of standard compliance procedures. 📊 *STOCKS:* DRREDDY | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Filing
Dr. Reddy's hits 52-week high on strong pipeline momentum
Dr. Reddy's shares hit a 52-week high *despite* USFDA observations, as investors focused on its advancing biologics pipeline and broader pharma sector rally. The stock surged **14%** in recent weeks, outperforming the Nifty Pharma index. Positive sentiment stems from new product expectations and improved market outlook. 📊 *STOCKS:* DRREDDY | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
FDA issues 7 observations on Dr. Reddy's plant
*FDA issues 7 observations on Dr. Reddy's plant* after inspecting its Hyderabad biologics facility, as noted in a new Form 483. This could delay approvals or trigger follow-up actions if not addressed promptly. While not a ban, it raises compliance concerns for the US-bound drugmaker. **Seven observations** signal moderate regulatory risk. 📊 *STOCKS:* DRREDDY | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDA
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8.8K Cr 0.8% | ₹8.8K Cr 3.0% | ₹8.6K Cr 0.5% | ₹8.5K Cr 1.8% | ₹8.4K Cr 4.3% | ₹8.0K Cr 4.4% | ₹7.7K Cr 8.2% | ₹7.1K Cr |
| Op. Profit | ₹1.9K Cr 6.1% | ₹2.0K Cr 7.5% | ₹2.2K Cr 8.8% | ₹2.0K Cr 12.1% | ₹2.3K Cr 9.5% | ₹2.1K Cr 2.5% | ₹2.1K Cr 16.3% | ₹1.8K Cr |
| OPM | 22.0% 4.3% | 23.0% 8.0% | 25.0% 8.7% | 23.0% 14.8% | 27.0% 3.8% | 26.0% 7.1% | 28.0% 7.7% | 26.0% |
| Net Profit | ₹1.2K Cr 11.0% | ₹1.3K Cr 5.2% | ₹1.4K Cr 11.2% | ₹1.6K Cr 13.0% | ₹1.4K Cr 4.6% | ₹1.3K Cr 3.6% | ₹1.4K Cr 6.3% | ₹1.3K Cr |
| EPS (₹) | 14.5 10.2% | 16.14 5.0% | 16.99 11.0% | 19.09 12.7% | 16.94 12.6% | 15.05 9.8% | 16.69 6.3% | 15.7 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹33.7K Cr 3.2% | ₹32.6K Cr 16.5% | ₹28.0K Cr 13.5% | ₹24.7K Cr 14.5% | ₹21.5K Cr 13.1% | ₹19.0K Cr 8.7% | ₹17.5K Cr 13.4% | ₹15.4K Cr 8.2% | ₹14.3K Cr 0.6% | ₹14.2K Cr |
| Expenses | ₹27.2K Cr 13.1% | ₹24.1K Cr 20.0% | ₹20.1K Cr 10.3% | ₹18.2K Cr 2.4% | ₹17.8K Cr 17.2% | ₹15.2K Cr 0.9% | ₹15.0K Cr 22.6% | ₹12.3K Cr 2.8% | ₹11.9K Cr 1.8% | ₹11.7K Cr |
| Op. Profit | ₹6.5K Cr 24.5% | ₹8.5K Cr 7.7% | ₹7.9K Cr 22.6% | ₹6.5K Cr 71.7% | ₹3.8K Cr 2.7% | ₹3.9K Cr 56.4% | ₹2.5K Cr 22.1% | ₹3.2K Cr 35.2% | ₹2.4K Cr 4.9% | ₹2.5K Cr |
| OPM | 19.0% 26.9% | 26.0% 7.1% | 28.0% 7.7% | 26.0% 52.9% | 17.0% 15.0% | 20.0% 42.9% | 14.0% 33.3% | 21.0% 31.3% | 16.0% 5.9% | 17.0% |
| Other Income | ₹1.4K Cr 22.6% | ₹1.1K Cr 23.1% | ₹909 Cr 6.4% | ₹971 Cr 75.0% | ₹555 Cr 65.7% | ₹335 Cr 50.0% | ₹670 Cr 75.9% | ₹381 Cr 145.8% | ₹155 Cr 9.9% | ₹172 Cr |
| Interest | ₹374 Cr 32.2% | ₹283 Cr 65.5% | ₹171 Cr 19.6% | ₹143 Cr 49.0% | ₹96 Cr 1.0% | ₹97 Cr 1.0% | ₹98 Cr 10.1% | ₹89 Cr 12.7% | ₹79 Cr 25.4% | ₹63 Cr |
| Depreciation | ₹2.1K Cr 20.8% | ₹1.7K Cr 15.9% | ₹1.5K Cr 17.6% | ₹1.3K Cr 7.3% | ₹1.2K Cr 5.2% | ₹1.2K Cr 5.7% | ₹1.2K Cr 2.5% | ₹1.1K Cr 5.4% | ₹1.1K Cr 4.9% | ₹1.0K Cr |
| PBT | ₹5.4K Cr 29.8% | ₹7.7K Cr 6.7% | ₹7.2K Cr 19.1% | ₹6.0K Cr 97.6% | ₹3.1K Cr 6.1% | ₹2.9K Cr 52.9% | ₹1.9K Cr 19.3% | ₹2.3K Cr 73.0% | ₹1.4K Cr 13.1% | ₹1.6K Cr |
| Tax % | 23.0% 8.0% | 25.0% 8.7% | 23.0% 8.0% | 25.0% 13.8% | 29.0% 9.4% | 32.0% 557.1% | -7.0% 141.2% | 17.0% 46.9% | 32.0% 68.4% | 19.0% |
| Net Profit | ₹4.2K Cr 27.4% | ₹5.7K Cr 2.6% | ₹5.6K Cr 23.8% | ₹4.5K Cr 106.6% | ₹2.2K Cr 11.8% | ₹2.0K Cr 3.7% | ₹2.0K Cr 3.9% | ₹1.9K Cr 105.9% | ₹947 Cr 26.7% | ₹1.3K Cr |
| EPS (₹) | 50.27 25.8% | 67.77 1.3% | 66.87 23.5% | 54.14 106.4% | 26.23 11.8% | 23.47 3.7% | 24.38 3.8% | 23.49 105.9% | 11.41 26.8% | 15.59 |
| Div Payout | 16.0% 33.3% | 12.0% 0.0% | 12.0% 20.0% | 15.0% 34.8% | 23.0% 9.5% | 21.0% 0.0% | 21.0% 23.5% | 17.0% 51.4% | 35.0% 34.6% | 26.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹84 Cr 1.2% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr 0.0% | ₹83 Cr |
| Reserves | ₹35.9K Cr 7.4% | ₹33.5K Cr 18.8% | ₹28.2K Cr 21.4% | ₹23.2K Cr 21.3% | ₹19.1K Cr 8.9% | ₹17.6K Cr 13.2% | ₹15.5K Cr 11.3% | ₹13.9K Cr 11.6% | ₹12.5K Cr 2.5% | ₹12.2K Cr |
| Borrowings | ₹5.9K Cr 25.2% | ₹4.7K Cr 133.6% | ₹2.0K Cr 48.6% | ₹1.3K Cr 60.2% | ₹3.4K Cr 11.6% | ₹3.0K Cr 37.1% | ₹2.2K Cr 42.4% | ₹3.8K Cr 24.3% | ₹5.1K Cr 3.1% | ₹4.9K Cr |
| Other Liabilities | ₹12.5K Cr 27.6% | ₹9.8K Cr 14.9% | ₹8.5K Cr 12.5% | ₹7.6K Cr 6.0% | ₹7.1K Cr 20.9% | ₹5.9K Cr 9.3% | ₹5.4K Cr 18.8% | ₹4.6K Cr 3.2% | ₹4.7K Cr 5.2% | ₹4.5K Cr |
| Total Liabilities | ₹54.4K Cr 13.2% | ₹48.0K Cr 23.8% | ₹38.8K Cr 20.4% | ₹32.2K Cr 8.3% | ₹29.7K Cr 11.9% | ₹26.6K Cr 14.5% | ₹23.2K Cr 3.6% | ₹22.4K Cr 0.3% | ₹22.3K Cr 3.2% | ₹21.7K Cr |
Assets | ||||||||||
| Fixed Assets | ₹20.6K Cr 13.1% | ₹18.2K Cr 74.8% | ₹10.4K Cr 13.1% | ₹9.2K Cr 13.5% | ₹8.1K Cr 1.0% | ₹8.2K Cr 19.8% | ₹6.8K Cr 4.7% | ₹7.2K Cr 3.2% | ₹7.0K Cr 0.5% | ₹6.9K Cr |
| CWIP | ₹2.0K Cr 19.0% | ₹2.5K Cr 73.8% | ₹1.4K Cr 37.8% | ₹1.0K Cr 20.3% | ₹1.3K Cr 17.4% | ₹1.6K Cr 2.0% | ₹1.5K Cr 47.7% | ₹2.9K Cr 15.4% | ₹3.5K Cr 4.4% | ₹3.3K Cr |
| Investments | ₹4.7K Cr 16.0% | ₹4.1K Cr 17.8% | ₹4.9K Cr 1.1% | ₹5.0K Cr 90.6% | ₹2.6K Cr 18.3% | ₹2.2K Cr 17.4% | ₹2.7K Cr 3.5% | ₹2.6K Cr 12.6% | ₹2.3K Cr 8.9% | ₹2.1K Cr |
| Other Assets | ₹27.1K Cr 16.2% | ₹23.3K Cr 5.8% | ₹22.0K Cr 29.6% | ₹17.0K Cr 4.2% | ₹17.7K Cr 21.3% | ₹14.6K Cr 20.1% | ₹12.2K Cr 25.3% | ₹9.7K Cr 1.0% | ₹9.6K Cr 3.5% | ₹9.3K Cr |
| Total Assets | ₹54.4K Cr 13.2% | ₹48.0K Cr 23.8% | ₹38.8K Cr 20.4% | ₹32.2K Cr 8.3% | ₹29.7K Cr 11.9% | ₹26.6K Cr 14.5% | ₹23.2K Cr 3.6% | ₹22.4K Cr 0.3% | ₹22.3K Cr 3.2% | ₹21.7K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹4.6K Cr 2.2% | ₹4.5K Cr 22.8% | ₹5.9K Cr 109.5% | ₹2.8K Cr 21.3% | ₹3.6K Cr 19.6% | ₹3.0K Cr 4.0% | ₹2.9K Cr 59.2% | ₹1.8K Cr 15.9% | ₹2.1K Cr 34.3% | ₹3.3K Cr |
| Investing CF | ₹-5.8K Cr 43.4% | ₹-4.0K Cr 1.8% | ₹-4.1K Cr 60.2% | ₹-2.6K Cr 13.7% | ₹-2.3K Cr 355.6% | ₹-495 Cr 35.6% | ₹-769 Cr 48.1% | ₹-1.5K Cr 21.5% | ₹-1.9K Cr 17.4% | ₹-1.6K Cr |
| Financing CF | ₹1.9K Cr 602.9% | ₹-376 Cr 86.0% | ₹-2.7K Cr 1009.9% | ₹-242 Cr 706.7% | ₹-30 Cr 98.8% | ₹-2.5K Cr 18.0% | ₹-2.1K Cr 380.4% | ₹-444 Cr 20.3% | ₹-369 Cr 78.3% | ₹-1.7K Cr |
| Net Cash Flow | ₹749 Cr 463.2% | ₹133 Cr 114.7% | ₹-907 Cr 30333.3% | ₹3 Cr 99.8% | ₹1.3K Cr 4863.0% | ₹-27 Cr 12.9% | ₹-31 Cr 75.0% | ₹-124 Cr 8.8% | ₹-114 Cr 142.6% | ₹-47 Cr |
| Free Cash Flow | ₹1.3K Cr 30.5% | ₹1.9K Cr 52.4% | ₹4.0K Cr 223.8% | ₹1.2K Cr 46.7% | ₹2.3K Cr 3.7% | ₹2.4K Cr 7.3% | ₹2.2K Cr 215.3% | ₹713 Cr 23.0% | ₹926 Cr 55.2% | ₹2.1K Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 101d 3.8% | 105d 1.9% | 107d 5.3% | 113d 18.9% | 95d 9.5% | 105d 11.7% | 94d 9.6% | 104d 6.1% | 98d 1.0% | 97d |
| Inventory Days | 260d 8.1% | 283d 22.0% | 232d 7.2% | 250d 8.4% | 273d 18.7% | 230d 15.8% | 273d 3.8% | 263d 6.7% | 282d 13.7% | 248d |
| Days Payable | 97d 16.4% | 116d 7.4% | 108d 2.7% | 111d 1.8% | 109d 9.0% | 100d 9.9% | 111d 8.3% | 121d 16.3% | 104d 18.2% | 88d |
| Cash Conv. Cycle | 264d 2.6% | 271d 17.3% | 231d 8.3% | 252d 2.7% | 259d 10.2% | 235d 8.2% | 256d 4.1% | 246d 10.5% | 275d 7.0% | 257d |
| Working Capital Days | 69d 41.5% | 118d 40.5% | 84d 37.7% | 61d 7.0% | 57d 3.4% | 59d 9.2% | 65d 66.7% | 39d 378.6% | -14d 141.2% | 34d |
| ROCE | 23.0% 14.8% | 27.0% 0.0% | 27.0% 92.9% | 14.0% 12.5% | 16.0% 45.5% | 11.0% 15.4% | 13.0% 62.5% | 8.0% 11.1% | 9.0% 52.6% | 19.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
HealthcarePharmaceuticals & Biotechnology